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ABSTRACT 
 
Aims: Severe pulmonary arterial hypertension (PAH) is an incurable disease whose exact 
mechanisms remain unknown. However, growing evidence highlights the role of inflammation 
and endothelin (ET) signaling. The lack of reliable models makes it difficult to investigate the 
pathophysiology of this disease. Our aim was therefore to develop a mouse model of severe PAH 
closely mimicking human condition to explore the role of Interleukin-6 (IL-6), and ET signaling 
in advanced PAH progression. 
Main methods: Young male SV129 mice received vascular endothelial growth factor receptor 
(VEGF-R) inhibitor (SU5416) (20 mg/kg) three times a week and were exposed to hypoxia (10% 
O2) for three weeks. Molecular analysis and histological assessment were examined using real-
time PCR, Western blot and immunostaining, respectively.  
Key findings: The developed murine model presented important characteristics of severe PAH 
in human: concentric neointimal wall thickening, plexogenic lesions, recruitment of 
macrophages, and distal arteriolar wall muscularization. We detected an increase of IL-6 
production and a stronger macrophage recruitment in adventitia of remodeled arterioles 
developing plexogenic lesions. Moreover, ET-1 and ET receptor A were up-regulated in lung 
lysates and media of remodeled arterioles. Recombinant IL-6 (50ng/ml) stimulated the 
proliferation and regulated endothelial cells in increasing ET-1 and decreasing ET receptor B. 
Significance: These data describe a murine model, which displays the most important features of 
human severe PAH. We assume that inflammation, particularly IL-6 regulating ET signaling, 
plays a crucial role in forming plexogenic lesions. This model is thus reliable and might be used 
for a better understanding of severe PAH progression and treatment. 
INTRODUCTION 
Pulmonary artery hypertension (PAH) is featured by aberrant inflammation, vasoconstriction and 
remodeling in small pulmonary arteries (PA) (Voelkel and Tuder, 1997). PA high pressure 
induces right ventricular (RV) hypertrophy, failure and ultimately death (Humbert et al., 2004; 
Tuder et al., 2001b). Severe PAH is characterized by hyperproliferation of PA smooth muscle 
cells (SMCs) and endothelial cells (ECs), creating medial and concentric neointimal thickening, 
and arteriolar lumens’ obliteration, leading to plexogenic lesions (Pietra et al., 2004; Tuder et al., 
1994). Current therapies including prostacyclins, endothelin receptor antagonists (ERA), and 
phosphodiesterase-5 inhibitors, focus on pulmonary arterial endothelial cell (PAEC) 
dysfunctions but not their hyperproliferation (Archer et al., 2010), hence, the annual mortality is 
still up to 15% (Thenappan et al., 2007). This relative inefficacy highlights a strong demand in 
animal modeling with recapitulative pathophysiological changes of severe PAH. 
Although the prognosis of patients with inflammation-associated PAH (i.e. connective tissue 
disease- (CTD-) associated PAH, particularly systemic sclerosis- (SSc-) associated PAH) 
improved recently, it is still worse than that of idiopathic PAH (iPAH) (Condliffe et al., 2009; 
Fisher et al., 2006; Girgis et al., 2005; Kawut et al., 2003). While inflammatory disturbances are 
described in both iPAH and SSc-PAH, these aberrancies are more severe in SSc-PAH, which 
explains the clinical and outcome discrepancies between the two syndromes (Fisher et al., 2006; 
Hassoun et al., 2009; Kawut et al., 2003). This suggests an inappropriate control of inflammation 
in the treatment of severe PAH. 
Interleukin-6 (IL-6) concentration in patient plasma and lung tissues correlates with the severity 
and prognosis of the disease (Soon et al., 2010). IL-6 is elevated in most forms of PAH, 
especially CTD-PAH (Hassoun et al., 2009; Humbert et al., 1995; Itoh et al., 2006; Lesprit et al., 
1998). Subcutaneous injection of recombinant IL-6 (rIL-6) in rats (Miyata et al., 2001) and mice 
(Golembeski et al., 2005) induced PAH determined by medial thickening of small PA, Fulton 
index and right ventricular systolic pressure (RVSP), while IL-6 transgenic (IL-6 Tg+) mice 
spontaneously developed PAH with neointimal hyperplasia (Steiner et al., 2009). Moreover, IL-6 
knockout mice were resistant to increase RVSP under hypoxia (Savale et al., 2007). It is 
suggestible about the role of IL-6 in stimulating the proliferation of ECs and SMCs (Steiner et al., 
2009; Yao et al., 2006, 2007) leading to severe PAH. However, the source and mechanism of IL-
6 at the injured sites are questionable. In experimental PAH, increased inflammatory cells around 
and in remodeled lesions are accompanied with elevated cytokines/chemokines including IL-6 
and monocyte chemotactic protein-1 (MCP-1). In those models, PAH can be reversed or 
prevented by an anti-inflammation treatment (Burke et al., 2009; Mizuno et al., 2012; Price et al., 
2011). In PAH patients, macrophages accumulate around the plexogenic lesions (Tuder et al., 
1994). We therefore investigated whether IL-6 produced by the recruited macrophages at the 
injured sites promoted the development of arteriopathy and consequent severe PAH.  
Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor produced by ECs, acting via two 
receptors, endothelin receptor A (ETAR) on SMCs and endothelin receptor B (ETBR) on both 
SMCs and ECs. In PAH patients, plasma ET-1 is elevated and correlates with the severity and 
prognosis of the disease (Rubens et al., 2001). Particularly, ET-1 is overexpressed in PAECs and 
in plexogenic lesions (Giaid et al., 1993). Hence, ERA became one of the three main types of 
drug in current treatments. However, efficacy of ERA is limited in patients with CTD-PAH, 
especially SSc-PAH, which possesses a high level of inflammatory components such as 
increased IL-6 production (Hassoun et al., 2009; Itoh et al., 2006), revealing the governor role of 
inflammation in regulating several pathways including ET-1 in these patients. We therefore have 
hypothesized that IL-6 may be upstream of the ET-1 system and regulates ET-1 signaling in the 
severe PAH. 
 
MATERIALS AND METHODS 
 
Reagents 
The following antibodies were used: Purified rat-anti-mouse Mac-3 (cat. 550292), purified rat-
anti-mouse CD31 (cat. 550274) (BD Pharmingen), HIF-1α (cat. NB100-479) (Novus 
Biologicals), rabbit anti PCNA (cat. ab29), rabbit anti IL-6 (cat. ab6672), rabbit anti VEGF-R2 
(cat. ab2349) (Abcam), rat anti mouse F4/80 (cat. MCA 497GA) (AbD Serotect), rabbit antibody 
von Willebrand factor (cat. A008202) (Dako Glostrup, Denmark), phosphorylated Smad3 
(pSmad3) (cat. 9134S) (Cell Signaling), rabbit anti GAPDH (cat. G9545), αSMA (cat. 
A2547&F3777) (Sigma), Bcl-2 (cat. sc-7383), phosphorylated extracellular signal-regulated 
kinases (pERK1/2) (cat. sc-7383), C-Jun N-terminal kinase (pJNK) (cat. sc-6254), JNK (cat. sc-
571) (Santa Cruz), and endothelin A receptor (ETAR) (cat. ARE-001) (Alemone Labs). Vascular 
endothelial growth factor receptor (VEGF-R) inhibitor (SU5416) (cat. 13342) was purchased 
from Cayman Chemical Co. Recombinant human interleukin-6 (rhIL-6) (cat. 7270-IL-025/CF) 
was bought from R&D Systems.  
Experimental procedure for the development of a model of severe mouse PAH 
All animal procedures were performed in accordance with the Guidelines for animal 
experimentation established by the Kobe University Graduate school of Medicine, Japan. Mice 
were kept in a room with controlled temperature (22-24
o
C) under a 12-hour-light-dark cycle. 
Food and water were accessible ad libitum. The experimental design was modified from that of 
Ciuclan et al. (2011). Briefly, 3-week-old male SV129 wild-type mice (n=5-6 each group) 
received 20 mg/kg VEGF-R inhibitor (SU5416) (Hypoxia+SU), which was suspended in CMC 
[0.5% (w/v) carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 0.4% (v/v) 
polysorbate 80, 0.9% (v/v) benzyl alcohol in deionized water] or vehicle (CMC only) (Hypoxia) 
subcutaneously three times a week and were exposed to chronic normobaric hypoxia (10% O2) in 
a ventilated chamber for three weeks. The chamber was flushed with a mixture of room air and 
nitrogen and was opened on the alternate day during 20 min for injection, hygiene and feeding 
reason. The gas was recirculated. The hypoxic condition was monitored using an oxygen monitor 
(Fujikura, Japan). Control mice (Normoxia) were kept in the same room, under the same light-
dark cycle. 
Hemodynamic Measurements 
Each mouse was anesthetized by isoflurane (1.4 mg/kg) inhalation via face mask. Isoflurane gas 
machine was connected to room air for normoxic mice or hypoxic chamber for hypoxic and 
hypoxia+SU mice. To evaluate pulmonary arterial pressure (PAP), 10 min after inhalant 
anesthesia, the right ventricle was assessed at subxiphoid site by a percutaneously inserted 25G 
needle connected to a pressure transducer. Right ventricular systolic pressure (RVSP) and heart 
rate (HR) were recorded on a Macintosh computer using the MacLab system (Bioresearch 
Center). The results were exploited if the HR under these conditions ranged between 300 and 
500 beats per minute (bpm). After hemodynamic measurements, the chest was opened and the 
lung and heart were cleared of blood with phosphate buffered saline (PBS) via RV using 26G 
needle connected to a perfusion machine in constant pressure pump. Lung tissues were collected 
for histological and molecular profiling. The heart was removed. The RV was dissected from the 
left ventricle (LV) and septum (S), then the Fulton index (RV/LV+S) and RV mass [RV 
(mg)/body weight (g) (BW)] were determined. 
Histology, Immunohistochemistry (IHC) and Immunofluorescence (IF) 
The right lung (RL) was removed after tight suturing at the hilus and snap-frozen for molecular 
profiling assays. The left lung (LL) was inflated with 0.1 ml of 4% paraformaldehyde (PFA) 
through a cathlon 22G inserted into trachea and pumped with constant pressure. Cathlon was 
released and trachea was closely tied, then the LL was removed, fixed in 4% PFA overnight and 
processed into paraffin using a standard procedure. Transverse section was performed to divide 
the LL into four pieces which were arranged in sequence and embedded in the same paraffin 
cassette and cut at 4 μm thickness. Five LLs in each group and 8 sections of each lung were 
investigated.  
Lung specimens were de-paraffinized in a series of xylene baths. The slides were then rehydrated 
in graded ethanol and distilled water. To retrieve antigenicity, the tissue sections were incubated 
in trypsin 0.02% in 1xTBS for 8 min at 37
o
C for IL-6 or heated using microwave in 10 mM 
citrate buffer (pH 6.0) 15 min for the others.  
For IHC: After cooling in room temperature (RT) for 30 min, the sections were washed with 
PBS and immersed in PBS containing 3% hydrogen peroxide (H2O2) for 5 min and blocked with 
5% bovine serum albumin (BSA) in PBS for 20 min. Primary antibody was applied and 
incubated at 4⁰C overnight. For Mac3 staining, slides were blocked in 0.3% H2O2/40% 
Methanol/PBS for 1 h at RT. Following PBS washing, secondary antibody was applied 1 h at RT. 
3,3 '-diaminobenzidine (DAB) was used as a chromogen (Dako, Carpinteria, CA).  
For IF: The sections were washed with 0.05% Triton X in PBS (PBS-T) and blocked with 3% 
BSA/PBS-T for 20 min. Primary antibody was used at 4⁰C overnight. Following PBS-T washing, 
secondary antibody was applied at RT for 1 h protected from light. DAPI was added for 15 min 
for nuclei staining. Slides were incubated in autofluorescent-blocking reagent (CuSO4) for 60 
min and mounted.  
Image analysis 
Slides were examined using Keyence BIOZERO microscope (Keyence, Osaka, Japan). Each 
group included 5 mice, 8 sections per mouse were checked. In each section around 40 small PA 
(< 100 μm diameter) sections were blindly evaluated. For muscularization quantification, the 
intensity of muscularization of small PA was determined based on the circumferential staining of 
α-smooth muscle actin (SMA) as either non-muscularized (N) (when no or little SMA staining) 
or partially muscularized (P) (when < 75% SMA staining) or fully muscularized (F) (when ≥ 
75% SMA staining), then the percentage distribution of each calculated per group. The results 
were the mean of all. For PCNA quantification, the number of PCNA positive cells on the 
endothelial layer was manually scored. Macrophages were manually counted by two independent 
investigators using 400 x magnifications. A minimum of 40 fields/section or 40 small PA/section 
was examined. Results were presented as mean of macrophages/field or macrophages/vessel. 
Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) 
Total mRNA was isolated from RL tissue using Trizol reagent (Invitrogen) according to manual 
instruction and reversed transcribed using ReverTra Ace (Toyobo). 10ng cDNA was applied for 
real time polymerase chain reaction (RT-PCR) using Thunderbird SYBR qPCR Mix (Toyobo) 
with the Rotor-Gene Q Real Time PCR Systems (Qiagen, Germany). Specificity of amplified 
RT-PCR product was verified by melting curve analysis or agarose gel electrophoresis. Relative 
mRNA levels were analyzed with a quantitative comparative Ct method and normalized with 
GAPDH or 18S gene expression as internal control. The primers used in this experiments were 
listed in table 1. 
Immunoblotting 
Frozen RL were minced and homogenized in RIPA buffer containing protease inhibitor cocktail. 
The lysates were eluted with 1x Laemmli buffer and resolved on SDS-PAGE gel, transferred to 
Immobilon polyvinylidene difluoride membrane (Millipore, Bedford, MA). Membranes were 
blocked with 5% skim milk in Tris-buffered saline-Tween 20 (TBS-T) at RT for 1 h and 
incubated with the primary antibody in Can Get Signal solution (Toyobo) at 4
o
C overnight. 
Membranes were then washed 3 times with 1x TBS-T and incubated with the 2
nd
 antibody in Can 
Get Signal solution for 1 h at RT. The band was detected by using the Luminata Forte Western 
HRP Substrate (Millipore) and luminescence was observed on an ImageQuant LAS 4000 (GE, 
Japan). The membranes were then stripped with a solution containing SDS 1% and glycine 0.2% 
(pH=2) for 45 min at 50
o
C and GAPDH was stained. Bands were quantified with AlphaEaseFC 
software (Alpha Innotech Corporation) and normalized with GAPDH. 
Generating of primary pulmonary endothelial cells (pmPECs) 
Preparation of antibody-coated beads 
Sheep anti-rat IgG Dynabeads (cat. 110.35) (Invitrogen) was washed 6 times with sterile 0.1% 
BSA/PBS and resuspended at 80 millions beads/ml. Each wash was performed by sitting the 
beads on magnetic particle concentrator (MPC) (DynaMg-2 cat.12321D) (Invitrogen) for 1 min 
to allow the beads to sediment. Beads were then saturated with 10µl of Purified Rat-anti Mouse 
CD31 (CD-31) antibody. Coating was performed on a rotator standing at RT for 2 h. Beads were 
then washed 5 times as described above and resuspended in 200µl 0.1% BSA/PBS. 
Magnetic bead sorting to isolate endothelial cells from young murine lung 
Each 3 week-old mouse was anesthetized with pentobarbital (Kyoritsu-Seiyaku, Tokyo, Japan) 
and the thoracic cavity was assessed. The individual lung lobes (without the bronchi and 
surrounding connective tissue) were aseptically excised and immersed in ice-cold DMEM. The 
lobes were removed from the DMEM, finely minced by cutting around 100 times and then 
incubated with 15ml warm 0.1% collagenase/dispase solution in DMEM for enzymatic digestion 
for 45 min at 37
o
C on a rotator. After the 45 min incubation, the digested tissue suspension was 
transferred into a 20ml syringe attached to a 14G cannula and homogenized around 12 times into 
a single cell suspension. The resulting cell suspension was filtered through a 40-µm strainer and 
washed with 15ml isolation media (IM) (20% FBS/DMEM and 1x Penicillin/Streptomycin) to 
stop digestion. The filtered cell suspension was centrifuged for 5 min at 400g. After removal of 
the supernatant, the cell pellet was resuspended in 3ml 0.1% BSA/PBS; 22.5 µl prepared 
magnetic beads coated with anti-CD31 antibodies was added and mixed at RT for 12 min. The 
bead was then sedimented using the MPC for 1 minute. After the removal of the supernatant, the 
cell pellet was washed 5 times with 3ml of 0.1% BSA/PBS, each time remounted on the MPC 
and then resuspended and mixed well in 3ml of HuMedia EG2 medium (cat. KE-2510S) (Kurabo, 
Japan) with FBS 2% and growth factors and 1x penicillin/streptomycin (VL) and plated into a 
2% gelatin-coated 10cm disk. Total volume was brought to 10ml with VL in each disk. The 
alternating day, half of the medium was changed. The cells were cultured for an additional of 3-4 
days to reach 70-80% confluence. 
Resorting with magnetic beads coated anti-CD31 antibodies 
At the confluence of 70 to 80%, the cells were detached by 0.05% Trypsin/EDTA for 3 min. 
When cells were completely detached, 2ml of IM was added to inhibit trypsinization. Cell 
suspension was spin down for 5 min at 400g and cell pellet was resuspended in 2ml 0.1 % 
BSA/PBS. 10 µl prepared magnetic beads coated with anti-CD31 antibodies was added and 
rotated at room temperature for 12 min. Cells were washed 5 times with 0.1% BSA/PBS, each 
time mounted on MPC. Cells were then plated into a 2% gelatin-coated 10cm disk. The purity of 
pmPECs was determined using double immunofluorescent staining for CD31 and S100A4 
(fibroblast marker). 
Cell culture 
Activated macrophages transformed from human monocytic cell line (THP-1 cat. RCB1189) and 
mouse pancreatic endothelial cell line (MS1) were obtained from RIKEN Cell Bank and cultured 
at 37
o
C (5% CO2 and 95% air). THP-1 was cultured in RPMI Medium 1640 (Gibco) with 10% 
FBS. The experiment in vitro was carried out by culturing human macrophages transformed from 
THP-1under phorbol myristate acetate treatment (PMA) and then treating them in Hypoxia (1% 
O2) combined with SU5416 (15nM) for 24 h. The cells were collected and mRNA and protein 
IL-6 expression were checked. MS1 cells were cultured in complete medium consisting 
DMEM/high glucose (cat. D5796) (Sigma) with 10% FBS. pmPECs were established in the lab 
as stated above and cultured with VL medium. The cells were subcultured by 0.05% trypsin 
(Gibco). MS1 cells and pmPECs were subjected to 50ng/ml IL-6 treatment for 24 h. The cells 
were collected and mRNA expression of ET-1 and ETBR were checked. 
Proliferation assay 
To assess the cell viability, MS1 were seeded at a concentration at 1x10
4
 cells/well (96-well 
plate) and cultured in the incubator (5% CO2 and at 37°C) in a normal medium as describe above. 
24 h after seeding, the cells were starved using DMEM/High Glucose 0.2% FBS during 24 h. 
The cells were then treated with 50ng/ml IL-6 for 24 h. The cell viability was examined using the 
Cell Counting Kit WST-1 (cat. 345-06463) (Dojindo) according to the manufacturer’s protocol. 
Briefly 10μl of cell counting solution was added to each well, mixed and the cells were 
reincubated in incubator (5% CO2 and at 37°C). The formazan-dyes were detected by measuring 
the absorbance at 450 nm (reference wavelength 655 nm) after 1h, 2h and 4h.  
Data Analysis 
Results are presented as the mean ± SEM. The data distribution was tested using Kolmogorov-
Smirnov test. Normally distributed variables were analyzed by using an unpaired Student t test 
for direct 2-group comparisons and the post hoc Turkey test after a significant 1-way ANOVA F 
test for 3-group comparisons to identify which group differences accounted for significant 
overall ANOVA results. Variables not normally distributed were analyzed using nonparametric 
analysis with Kruskal-Wallis followed by Mann-Whitney U test. Statistical analysis was 
performed with the GraphPad Prism software package. P < 0.05 was considered significant. 
 
RESULTS 
 
Experimental model of severe PAH 
 
SU5416 aggravated the elevated PAP and RV hypertrophy created by hypoxic condition 
The murine model of severe PAH has been established by Ciuclan et al in 2011 (Ciuclan et al., 
2011) by treating adult C57/Bl6 mice with SU5416 in chronic hypoxic environment. However, 
others have failed to reproduce this model (Gomez-Arroyo et al., 2012). Therefore, we aimed to 
modify the procedure by using young SV129 mice with higher frequency of treatment with 
SU5416. After 3 weeks, a clear decrease in body weight was observed in Hypoxia+SU mice in 
comparison with Hypoxia (P < 0.05) and Normoxia (P < 0.01) mice. There was no significant 
difference between Hypoxia and Normoxia mice (Table 2).  
We observed an upregulation of cleaved caspase-3 in Hypoxia+SU group (P< 0.01 vs. Normoxia 
or Hypoxia), indicating an increased apoptosis (Figure 1B). Chronic hypoxia induced the 
elevation of RVSP in mice with either SU5416 or vehicle, compared with the mice under 
normoxia (RVSP=37mmHg; 29mmHg and 22.5mmHg; respectively). Importantly, treating with 
SU5416 induced a further increase of RVSP (Figure 1C). A RV hypertrophy was noted in 
Hypoxia (Fulton index, 0.40; RV/BW, 1.3; P < 0.01 vs. Normoxia, 0.31; 1.1) and was further 
elevated in Hypoxia+SU (Fulton index, 0.55; RV/BW, 1.8; P< 0.001 vs. Hypoxia) (Figure 1D, 
E). 
SU5416 augmented the muscularization of distal acinar arterioles and the thickening of 
arteriolar medial layer generated by hypoxia 
One characteristic of PAH is the muscularization of distal acinar arterioles. While the majority of 
normal lung small vessels was non-muscularized (N) (68%) and only a small number of fully 
muscularized (F) was noted (12%), Hypoxia and Hypoxia+SU mice showed a reduction in N 
percentage (53% and 32%, respectively), along with the elevation of F percentage (24% and 42%, 
respectively) after 3 weeks. Combination of SU5416 and hypoxia profoundly enhanced the 
degree of F (P< 0.0001 vs. Hypoxia) and decreased the level of N (P< 0.0001 vs. Hypoxia) 
(Figure 2B). 
Only SU5416 combined with hypoxia can cause plexogenic lesions 
To investigate the remodeling of small PA, we performed IHC of von Willebrand factor (vWF), 
an endothelial cell marker and double IF staining for vWF and SMA (Figure 2A). Histological 
examination revealed various degrees of concentric neointimal thickness in pulmonary arterioles, 
particularly the complete lumen obliteration by multiple layers of cells expressing vWF in 
Hypoxia+SU group (Figure 2Ac,f). On the contrary, no neointimal thickening lesions were 
observed and the endothelium still maintained monolayer in hypoxic and normoxic mice (Figure 
2Ab,d,e). 
Proliferative endothelial cells completely occluded the small lung arteries in hypoxia 
combined SU5416-treated mice 
To demonstrate whether the cells expressing vWF in plexogenic lesions were proliferating cells, 
we performed double IF staining for the proliferation marker proliferating-cell nuclear antigen 
(PCNA) and vWF. Cells expressing vWF in neointimal thickening lesions in pulmonary 
arterioles of Hypoxia+SU mice remarkably up-regulated PCNA contributing to plexogenic lesion 
formation (Figure 3Ac), whereas, that of hypoxic and normoxic mice exhibited minimal PCNA 
expression (Figure 3Aa,b). A three time increase in the amount of PCNA positive cells in 
endothelium of remodeled arterioles was noted in Hypoxia+SU compared with Hypoxia and 
Normoxia (P< 0.001), whereas no significant difference between hypoxic and normoxic mice 
(Figure 3B). 
 
Alteration of biomarkers, inflammatory profiles and signaling pathways in hypoxia 
combined SU5416-treated group 
 
Biomarker analysis revealed that angio-occlusion in SU5416-treated mice under hypoxia was 
the consequence of hyper-proliferation and resistance to apoptosis  
Since it has been previously showed that exposure to chronic hypoxia combined with VEGF-R 
inhibitor could generate an endothelial population which escaped from the apoptosis and became 
aberrantly proliferative (Taraseviciene-Stewart et al., 2001, 2006), we sought to investigate this 
phenomenon in Hypoxia combined SU5416-treated mouse model. VEGF-A mRNA was elevated 
in Hypoxia alone (P < 0.01 vs. Normoxia) and further enhanced in Hypoxia+SU (P < 0.05 vs. 
Hypoxia) (Figure 3D). VEGF-R2 mRNA and protein levels were up-regulated in Hypoxia+SU 
(P < 0.01 vs. Normoxia) (Figure 3E, 3F), but were not enhanced in mice under hypoxia only 
(Figure 3E, 3F). mRNA of MMP-9 was increased in the hypoxic group (P< 0.01 vs. Normoxia) 
and further induced in Hypoxia+SU group (P< 0.05 vs. Hypoxia) (Figure 3C). In addition, we 
assessed the expression of pJNK and pERK1/2, which are known as growing factors for PAECs. 
Protein level of pJNK and pERK1/2 in the lung lysates were remarkably raised in Hypoxia+SU-
treated mice (P< 0.05 vs. Hypoxia), while exposure to hypoxia only had no potent effect (Figure 
3I, 3J). Furthermore, quantitative RT-PCR and immunoblot were performed for Bcl-2, an anti-
apoptotic marker. Only Hypoxia+SU could increase mRNA and protein levels of Bcl-2 (P< 0.05 
vs. Hypoxia) (Figure 3G, 3H).  
Inflammatory profile altered in response to hypoxia with/without VEGF R inhibition 
To explore the possibility that inflammatory cell infiltration may contribute to the formation of 
neointimal thickening and occluded arterioles, we performed IHC for Mac3 antibody, a 
macrophage marker, and quantified the number of macrophages in the lungs and in the adventitia 
of lung arterioles. Hypoxia induced recruitment of macrophages to the lungs and the adventitia 
of arterioles (P< 0.01 vs Normoxia) (Figure 4Aa,b,d,e; 4B; 4C). Hypoxia+SU further increased 
these numbers two to three times (P< 0.0001 vs. Hypoxia) (Figure 4Ab,c,e,f; 4B; 4C). The 
results were supported by Western blot data that F4/80 expression in lung lysates significantly 
enhanced under hypoxic exposure (P< 0.05 vs. Normoxia) and three times greater in hypoxia 
combined with SU5416 treatment (P< 0.01 vs. Hypoxia) (Figure 4D). Moreover, monocyte 
chemotactic protein-1 (MCP-1), an important chemokine in recruitment and activation of 
macrophages, was also profoundly up-regulated in Hypoxia+SU only (P< 0.001 vs. Hypoxia and 
Normoxia) (Figure 4E). 
IL-6 and its receptor were elevated in the lungs under hypoxia combined SU5416 treatment 
To investigate the role of recruited macrophages in the adventitia of remodeled arterioles in the 
formation of plexogenic lesions, we concentrated on proinflammatory cytokine IL-6, being well 
known as one of the most important cytokines associated with PAH development. IHC (Figure 
5A a-c) and double IF staining (Figure 5A d-i) were carried out for IL-6 or IL-6 and SMA, 
respectively. Combination of SU5416 and chronic hypoxia induced abundant IL-6 in the 
adventitia of remodeled arterioles (Figure 5Ac,f,i), whereas, hypoxia alone only generated 
minimal expression (Figure 5Ab,e,h). No detectable signal was observed in normoxic mice 
(Figure 5Aa,d,g). Immunoblot and quantitative RT-PCR also confirmed the greater up-regulation 
of protein and mRNA IL-6 in Hypoxia+SU (P < 0.001 and P< 0.05 vs. Hypoxia, respectively), 
while no significant increase was observed in hypoxic mice (P=0.3 and 0.14, vs. Normoxia, 
respectively) (Figure 5B, 5C). Similarly, IL-6 receptor mRNA was significantly raised in 
Hypoxia+SU mice (P< 0.05 vs. Hypoxia and Normoxia) only. (Figure 5D). 
Hypoxia inducible factor (HIF-1α) signaling machinery, transforming growth factor β (TGF-
β)/bone morphogenic protein (BMP)/Smad axis was perturbed in mice exposed to hypoxia 
combined with/without SU5416 
As HIF-1α is known to be elevated in lung of patients with idiopathic PAH, we aimed to 
determine HIF-1α level. Western blot results described a marked elevation of HIF-1α protein in 
the lung of hypoxic mice (P < 0.05 vs. Normoxia) and this effect was further increased in 
Hypoxia+ SU group (P < 0.01 vs. Hypoxia) (Figure 6A). We assessed the gene expression of 
TGF- β/BMP/Smad axis. TGF- β mRNA was up-regulated under hypoxic exposure (P < 0.05 vs. 
Normoxia), with no further influence created by SU5416 combination (Figure 6C). In contrast, 
protein level of phosphorylated Smad3, downstream component of TGF- β signaling which 
modulated cellular response linked to vascular remodeling, was slightly elevated  in hypoxic 
treatment (P=0.4 vs. Normoxia) but six times greater promoted in Hypoxia+SU (P < 0.05) 
(Figure 6B). A significant reduction in BMPRII mRNA expression was noted in hypoxic mice (P 
< 0.05 vs. Normoxia), with no advanced effect in Hypoxia+SU mice (Figure 6D). 
 
Disturbance in endothelin pathway under combination of chronic hypoxia and VEGF R 
inhibition 
There was an increase in ET-1 and ETAR mRNA (P< 0.01 vs. Hypoxia and Normoxia) (Figure 
7A, 7B) and a reduction in ETBR mRNA (P< 0.05 vs. Hypoxia; P < 0.01 vs. Normoxia) (Figure 
7D) under combination treatment of hypoxia and SU5416, while, no influence of hypoxic 
treatment was noted in ET-1, ETAR and ETBR mRNA levels (Figure 7A, 7B, 7D). Similarly, 
ETAR protein was augmented in Hypoxia+SU-treated mice only (Figure 7C). Interestingly, 
immunostaining results depicted a colocalization of ETAR (red) and SMA (green) in the media 
of arterioles in Hypoxia+SU-treated mice only (Figure  7Ec,f). No colocalized signal in hypoxic 
and normoxic mice was recorded (Figure 7Ea,b,d,e).  
 
In vitro influence of Hypoxia combined with SU5416 on IL-6 expression and effect of IL-6 
on endothelin signaling pathway 
 
Hypoxia combined with SU5416 promoted IL-6 expression in human macrophages 
In cultured human macrophages, IL-6 mRNA and protein expression were increased in 
Hypoxia+SU-treated cells (P < 0.05 vs. Hypoxia; P < 0.01 vs. Normoxia), while exposure to 
hypoxia only enhanced slightly IL-6 protein (P=0.2 vs. Normoxia) (Figure 8). 
Recombinant human IL-6 stimulated the proliferation and regulated ECs in increasing ET-1 
and decreasing ETBR expression  
In MS1 and pmPECs, IL-6 treatment (50ng/ml) increased ET-1 mRNA (P< 0.05 vs. controls) 
and reduced mRNA ETBR expression (P< 0.05; P< 0.01 vs. controls in MS1 and in pmPECs, 
respectively) (Figure 9). IL-6 treatment enhanced proliferation of MS1 cells (P< 0.001 vs. 
controls) detected by WST-1 assay (Figure 9C). 
 
DISCUSSION 
 
The newly optimized mouse model of severe PAH 
The hallmark of severe PAH patients is the remodeling in small lung vessels characterized by 
concentric neointimal thickening, plexogenic lesions, recruitment of inflammatory cells, and 
distal arteriolar wall muscularization (Tuder et al., 1994). To date, several rat models of severe 
PAH closely mimicking human conditions have been established. The closest one combines 
hypoxia with a SU5416 treatment (Abe et al., 2010; Taraseviciene-Stewart et al., 2001). 
However, this model could not provoke the inflammatory response in the rat lung (Abe et al., 
2010; Taraseviciene-Stewart et al., 2001), a common phenomenon observed in patients (Cool et 
al., 1997; Hall et al., 2009; Pinto et al., 2004; Tuder et al., 1994). It might explain the 
discrepancy in application of several drugs such as simvastatin (Taraseviciene-Stewart et al., 
2006), which provides a good recovery in the rat model, yet shows no beneficial effects in 
humans (Kawut et al., 2011). Problems have occurred in establishing the severe PAH in mouse, 
the common alternative to rats as laboratory animals. First, mice are less vulnerable to hypoxia 
than rats regarding pulmonary vessel remodeling (Dempsey et al., 2009; Frank et al., 2008; 
Nozik-Grayck et al., 2008). Hypoxia induces genes involved in EC proliferation in rats but not in 
mice (Hoshikawa et al., 2003). Second, the accumulation of SU5416 in lungs is less in mice. 
Higher systemic and renal clearance of SU5416 in mice was noted and SU5416 is hepatically 
metabolized by CYP450-1A, a cytochrome distinctly expressed in animal species (Martignoni et 
al., 2006; Nelson et al., 2004; Ye et al., 2006). Repeated administration of SU5416 induces 
several CYP450 in the liver, which differ between the two species (Craft et al., 2002; Martignoni 
et al., 2006). Ciuclan et al. successfully generated the severe PAH model from adult C57/Bl6 
mice  (Ciuclan et al., 2011). However, this protocol could not be reproduced in other workplaces 
(Gomez-Arroyo et al., 2012). Different mouse strains may react differently and younger mice 
with rapidly maturing lungs are more vulnerable when exposed to hypoxia (Stenmark et al., 
2006). We thus used young SV129 mice, which were proven more sensitive to hypoxia than 
C57/Bl6 (Tada et al., 2008), and increased the frequency of SU5416 treatment.  
Consistent with previous reports about the role of SU5416 in inducing a sustained death of 
pulmonary ECs (Ciuclan et al., 2011; Sakao et al., 2005; Taraseviciene-Stewart et al., 2001), we 
observed a marked increase of cleaved caspase-3 in our model. Hypoxia-induced inflammation 
(Burke et al., 2009; Savale et al., 2009) together with the apoptotic bodies from apoptotic ECs 
may stimulate the release of IL-6 and MCP-1 (Berda-Haddad et al., 2011; Curtis et al., 2009), 
which in turn, may recruit macrophages in the injured vessels, which might ultimately lead to the 
development of severe PAH. 
IL-6 as a potential conductor in severe PAH 
IL-6, an important proinflammatory cytokine in PAH progression, is produced by activated 
macrophages, fibroblasts, ECs and SMCs. Indeed, IL-6 is steadily increased and considered 
prognosis factor in idiopathic and inflammation-associated PAH (Humbert et al., 1995; Li et al., 
2012; Nishimaki et al., 1999; Soon et al., 2010). Our study demonstrated an up-regulation of IL-
6 in Hypoxia+SU, especially an abundance of IL-6 in the adventitia of remodeled arterioles. 
Consistently, IL-6 elevates in and around the angio-obliterating lesions in SU+ovalbumin rat 
PAH model (Mizuno et al., 2012). It is possible that IL-6 per se may stimulate the proliferation 
of SMCs and ECs (Steiner et al, 2009; Yao et al., 2006, 2007), and consequently form medial 
and concentric neointimal thickening and plexogenic lesions, the fingerprints of severe PAH 
(Tuder et al., 1994). Our experiments confirmed this idea by showing that 50ng/ml IL-6 
stimulated the MS1 cell growth in vitro. IL-6 triggers ECs at a dose dependent manner, i.e. ≥ 
50ng/ml IL-6 render cerebral ECs proliferative, but 25ng/ml IL-6 do not (Yao et al., 2006). In 
vivo, even though IL-6 is slightly elevated in hypoxic mice, neither arteriolar obliteration nor 
proliferative ECs was observed. This is consistent with previous studies indicating that hypoxia 
alone cannot generate proliferation of ECs (Steiner et al., 2009; Voelkel and Tuder, 2000; Yu 
and Hales, 2011). Hypoxia creates only a short-course raise of IL-6 peaking at day 7
th
 and 
returning to the baseline at day 14
th 
(Savale et al., 2007). IL-6 Tg
+ 
mice also display most 
important features of severe PAH under hypoxia (Steiner et al., 2009). However, transgenic 
models do not fully mirror the human condition. In this model, the authors show that IL-6 
genetic overexpression induced PAH is worsened by hypoxia. The IL-6 expression levels 
however were not measured, which makes difficult to establish how strong the development of 
PAH correlates with IL-6 or with hypoxia. Moreover, it is not clear whether IL-6 produced by 
Clara cells affects PA remodeling by directly targeting vessel wall cells or by indirect effects 
mediated by inflammatory cells themselves. In the present study, we have shown that the 
worsening of the PAH by SU5416 treatment is associated with an increased expression of IL-6. 
Ciuclan et al. depicted an elevation of mRNA IL-6 and macrophages in the lung of their model, 
too (Ciuclan et al., 2011). Nevertheless, no relationship between macrophages, IL-6 and 
arteriolar remodeling had been cited. Using Mac3 marker, we described an accumulation of 
macrophages in the similar areas of IL-6 expression, which suggested that IL-6 may be secreted 
from adventitial macrophages of remodeled arterioles. This data was supported by our work in 
vitro indicating that macrophages produced increased IL-6 under hypoxia combined with 
SU5416. 
Enormous infiltration of macrophages is often mentioned within and around the remodeled 
arterioles in severe PAH. Macrophages directly release MMP-9 (Mautino et al., 1999 ) and 
MCP-1 (Yoo et al., 2005; Yoshimura et al., 1989), which, as a positive feedback, recruit 
macrophages (Taylor et al., 2006). In mice, combination of MMP-9 overexpression and 
monocrotaline administration generates PAH with occluded precapillary vessels and sustained 
macrophage infiltration ( George et al., 2012). In vitro, increased MMP-9 by IL-6 causes ECs 
and SMCs to proliferate (Yao et al., 2006, 2007). MCP-1 is depicted in ECs, SMCs, and 
macrophages within remodeled arterioles and closely associated with pulmonary vascular 
resistance in PAH patients (Kimura et al., 2001). MMP-9 and MCP-1 are also secreted by ECs 
(Genersch et al., 2000; Kimura et al, 2001; Sanchez et al., 2007; Yao et al., 2006) in PAH. 
Therefore, their high level in Hypoxia+SU may result from the overproduction of proliferative 
ECs, which in turn contributing to the recruitment and migration of macrophages (Sanchez et al., 
2007). 
IL-6 moderates hyperproliferation and anti-apoptosis of ECs through VEGF, MAPK signaling 
and Bcl-2. VEGF and VEGF-R2 are the key components for EC survival and high levels of them 
have been found in the lung, particularly in plexogenic lesions of PAH patients (Tuder RM et al., 
1994). VEGF and VEGF-R2 are up-regulated by IL-6 and trigger proliferation of ECs via 
pERK1/2. Consistently, blocking VEGF or VEGF-R2 abolishes IL-6-induced proliferation 
(Steiner et al., 2009; Yao et al., 2006). JNK, another MAPK component, is not only an anti-
apoptosis but a proliferative factor as well (Ma et al., 2012). Activation of pJNK induces 
prosurvival signaling in ECs (Salameh et al., 2005), increases the proliferation and decreases the 
apoptosis of bovine PAECs (Ma et al., 2012). We therefore examined protein levels of VEGF-R2, 
pERK1/2 and pJNK in our model and recorded the elevation of all these parameters in 
Hypoxia+SU. In PAH patients, Bcl-2 is increased in the lungs (Geraci et al., 2001) and in 
PAECs associated with irreversibility of the disease (Lévy et al., 2007). Furthermore, Bcl-2 is 
increased in IL-6 Tg
+
 mice (Steiner et al., 2009) and induced by VEGF in serum-starved ECs 
(Cai et al., 2003; Gerber et al., 1998). In our model, Bcl-2 could be indirectly induced by IL-6 
through VEGF to create an overproliferative EC population. 
HIF-1α, another IL-6-regulated factor, is highly expressed in angio-obliterative proliferative 
lesions in PAH patients (Tuder et al., 2001a). We noted a positive correlation between IL-6 and 
HIF-1α in Hypoxia and Hypoxia+SU, while no association between them was observed in 
Ciuclan’s study (Ciuclan et al., 2011). The further augmentation of HIF-1α in Hypoxic+SU mice 
may be partly induced by the activation of IL-6/Stat3/HIF-1α axis, an important pathway in 
cancer cells (Grivennikov et al., 2009; Lang et al., 2007; Nilsson et al., 2010), and mentioned in 
rats with severe PAH (Mizuno et al., 2012). IL-6 triggers phosphorylation of Stat3 (Heikkila et 
al., 2008), leading to up-regulation of HIF-1α either by blocking its degradation or elevating its 
synthesis (Jung et al., 2005). Interestingly, activation of Stat3 by IL-6 mediates expression of 
miR-17/92, resulting to the repression of BMPRII protein (Brock et al., 2009), an important 
inhibitor of EC and SMC proliferation. The translational interference of IL-6 to BMPRII 
explains the difference only at the protein level of BMPRII but not at the mRNA between 
Hypoxia and Hypoxia+SU. 
IL-6 potentially regulated endothelin signaling in severe PAH 
IL-6 enhances TGF-β-dependent Smad3 signaling (Zhang et al., 2005). pSmad3 potentiates 
TGF-β-induced ET-1 from ECs (Castanares et al., 2006; Rodríguez-Pascual et al., 2003, 2004). 
We demonstrated that the increased TGF-β expression in Hypoxia and Hypoxia+SU was not 
different, but pSmad3 expression was elevated only in the latter group, which might indicate that 
pSmad3 contributed to the elevation of ET-1 expression. 
ETAR and ETBR on the SMCs mediate the vasoconstriction and proliferation of vascular SMCs 
(Davie et al., 2002; Kedzierski and Yanagisawa, 2001; Levin, 1995), while ETBR on the ECs 
induces the release of vasodilator and anti-proliferative modulators. Furthermore, ETBR 
participates in the clearance of ET-1 from the lungs and inhibition of endothelin converting 
enzyme-1 (ECE-1) (Fukuroda et al., 1994; Naomi et al., 1998). In patients with PAH, ET-1 
plasma levels are elevated and correlated with the severity and prognosis of the disease (Rubens 
et al., 2001). ET-1 is particularly overexpressed in plexogenic lesions and PAECs (Giaid et al., 
1993). Similarly, we observed a high level of ET-1 mRNA in Hypoxia+SU. However, in 
hypoxia alone, ET-1 did not change. Several researches indicate the positive (Kourembanas et al., 
1993; Perrella et al, 1992) or negative/neutral (Markewitz et al., 1995) effect  of hypoxia on ET-
1 production. One reason cited by those authors to explain the negative/neutral effect is the 
inhibitive role of nitric oxide (NO) on ET-1 production of ECs.  In hypoxic mice, we also 
observed the increase of endothelial NO synthase (eNOS) gene expression in the hypoxic group 
(data not shown). In addition, we observed an upregulation of  ETAR mRNA and protein in 
Hypoxia+SU. Immunofluorescence revealed the presence of ETAR on the SMCs, only in 
Hypoxia+SU. Moreover, in vitro, IL-6 raised the mRNA ET-1 in pmPECs and MS1, consistent 
with previous report showing that IL-6 is a potent stimulator of ET-1 production by EC (Kahaleh 
and Fan, 1997). This effect is dose dependent (Kahaleh and Fan, 1997), because low dose of IL-6 
(0.5-10ng/ml) has no effect on ECs of the aorta, PA, and retinal microvessels on the release of 
ET-1 (Kanse et al., 1991). This is consistent with our results in mice under hypoxia alone 
showing slightly elevated IL-6 and hence no change of ET-1. The up-regulation of both ET-1 
and ETAR may activate ERK1/2 inducing SMC proliferation (Chen et al., 2009; Yogi et al., 
2007; Zhang et al., 2003). Furthermore, we noted ETBR reduction in vitro and in vivo. We have 
measured ET-1 expression at the mRNA level only. Nevertheless, we can speculate that the 
reduced ET-1 clearance and ECE-1 inhibition consequent to a reduction of ETBR expression 
might potentiate ET-1 peptide abundance in lungs of Hypoxia+SU mice. Since ETBR expression 
in SMC increases in PAH (Bauer et al., 2002), the overall reduction of ETBR that we observed 
might be underestimated in the ECs, which implies that the vasodilation and antiproliferation 
mediated by ETBR on ECs might be particularly down-regulated. This also might explain why 
selective ETAR antagonist is not superior to non-selective ERA in human PAH treatment (Benza 
et al., 2006; Christian et al., 2008).  
 
CONCLUSION 
We have optimized a model of severe PAH by using young SV129 mice and a combination of 
hypoxia and sustained VEGF-R inhibition. These mice exhibited most important characteristics 
of severe PAH observed in humans: concentric neointimal wall thickening, plexogenic lesions, 
recruitment of macrophages, and distal arteriolar wall muscularization. Using this model, we 
have demonstrated the role of adventitia-derived IL-6 and recruited macrophages in adventitia of 
remodeled vessels in the development of plexogenic lesions, suggesting IL-6 in the adventitia as 
a potential therapeutic target. Moreover, we produced evidences for a potential regulation of ET-
1 signaling by IL-6 in the development of severe PAH. The cells in plexogenic sites were 
proliferative ECs with high expression of VEGF, VEGF-R2, Bcl-2, and HIF-1α, inferring the 
cancer-like features of PAH with excess proliferation and impaired apoptosis. These results may 
explain the difficulties in treatment of severe human PAH with available drugs. Therefore, this 
model can be reliable in investigating pathophysiological mechanisms and testing new 
medications for treating severe PAH patients. 
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 FIGURE LEGENDS 
Figure 1: Effect of vascular endothelial growth factor receptor (VEGFR) inhibitor 
(SU5416) on lung vessels. (A) Experimental setup: three-week-old male SV129 mice were 
injected subcutaneously three times a week with SU5416 (20mg/kg) or vehicle combined with 
exposure to hypoxic environment (10% O2) for three weeks. Normoxia was used as control. (B, 
C) Representative immunoblot protein expression and quantification of cleaved caspase-3. Anti-
GAPDH was used as a loading control. Diagrams show the densitometry quantification (n=4). 
(D) Right ventricular (RV) systolic pressure (RVSP) was recorded via needle directly assessed to 
RV lumen at subxiphoid site. (E) RV/left ventricle plus septum weight ratio (Fulton index). (F) 
RV (mg)/body weight (g) ratio. Data are expressed as means ± SEM for 5-6 mice per group. 
Statistical differences (*P<0.01, **P< 0.001, ***P< 0.0001) were determined using t test. 
 
Figure 2: SU5416 enhanced chronic hypoxia-induced vascular remodeling with 
development of neointimal occlusive lesions. (A) (a-f) Representative double 
immunofluorescent  (a-c) and immunohistochemistry (d-f) staining images of the predominantly 
remodeled vessel showed completely occluded arterioles with multilayer of cells expressing 
vWF and severe thickening of medial layer of arterioles in hypoxia combined SU5416-treated 
mice (c, f). No neointimal hyperplastic or occlusive lesions were noted and endothelium still 
remained monolayer in hypoxic and normoxic mice (a, b, d, e). Medial layer was thicker in 
hypoxic mice (b, e), but thinner than in hypoxia combined SU5416-treated mice (c, f).  
(B) Vascular muscularization: 4-µm lung sections were stained with antibodies for α-smooth 
muscle actin (SMA) and von Willebrand factor (vWF). Forty pulmonary arterioles (< 100 µm) 
per section were blindly evaluated to the source of tissue. Based on the circumferential staining 
of SMA, the vessel was determined as either non-muscularized (N), or partially muscularized (P) 
(<75% staining), or fully muscularized (F) (≥75% staining), then the percentage distribution of 
each calculated per group. Scale bars: 50 μm. Statistical differences (***P< 0.001, ****P< 
0.0001) were expressed by analysis of variance. 
 
Figure 3: Hypoxia combined SU5416 induced endothelial cellular proliferation. (A) 
Representative  double immunofluorescent  staining images showed concentric neointimal 
proliferation with increasing Proliferating Cell Nuclear Antigen (PCNA) expression in the 
thicken endothelial layer (expressing vWF) leading to arteriole occlusion in hypoxia combined 
SU5416-treated mice (c), whereas, endothelium still remained monolayer with low PCNA 
expression in hypoxic and normoxic mice (a, b). Scale bars: 50 μm. (B) Quantification of 
endothelial cells expressing PCNA/vessel. (C, D, E, G) The relative mRNA expression of 
VEGF-A, VEGF-R2, MMP-9 and Bcl-2 to GAPDH in lung lysates was analyzed by quantitative 
real-time RT-PCR (n=5-6). (F, H, I, L) Representative immunoblot protein expression of VEGF-
R2, phosphorylated c-Jun N-terminal kinases (pJNK), phosphorylated extracellular-signal 
regulated kinases and Bcl-2 (pERK1/2) and (J, K, M) quantification of pJNK/JNK, 
pERK1/2/GAPDH and Bcl-2/GAPDH. Anti-GAPDH was used as a loading control, (n=4). 
Statistical differences (*P <0.05, **P< 0.01, ***P< 0.001) were determined using t test.  
 
Figure 4: Increase of inflammatory response in hypoxia combined SU5416-treated mice 
versus in hypoxic and normoxic mice. (A) Representative immunohistochemistry staining 
images showed markedly increased recruitment of macrophages (Mac3 marker) in whole lung 
(a,b,c) and particularly in the adventitia of remodeled arterioles in hypoxia combined SU5416-
treated mice (f) versus in hypoxic (e) and normoxic (d) mice. Scale bars: 50 μm. (B) The number 
of macrophages in lung using the 400 x magnifications was manually counted by two 
independent individuals. A minimum of forty fields/lung section was counted and the result was 
the mean of macrophages/field. (C) The number of macrophages in adventitia was counted by 
two independent individuals using 400 x magnifications. A minimum of forty arterioles/lung 
section was counted and the result was the mean of macrophages/vessel. (D) Representative 
immunoblot protein expression and quantification of F4/80 in lung lysates of hypoxia combined 
SU5416-treated mice as well as normoxic and hypoxic mice. GAPDH was used as a loading 
control, (n=4). (E) Plots showed mRNA expression of MCP-1in lung lysates, normalized to 
GAPDH, (n=5-6). Statistical differences (*P< 0.05, **P< 0.01, ***P< 0.001) were expressed by 
analysis of variance.  
 
Figure 5: Up-regulation of interleukin-6 (IL-6) and IL-6 receptor in hypoxia combined 
SU5416-treated mice. (A) Representative immunohistochemistry (a-c) and double 
immunofluorescent (d-i) staining images showed abundant IL-6 expression in the adventitia of 
remodeled arterioles in hypoxia combined SU5416-treated mice (c,f,i), whereas no detection in 
normoxic mice (a,d,g) and little expression in hypoxic mice (b,e,h). Scale bars: 50 μm. (B) 
Representative immunoblot and quantification of IL-6 expression in lung lysates of hypoxia 
combined SU5416-treated mice as well as hypoxic and normoxic mice. Immunoblots were 
representative of lungs from 4 individuals for each group. (C, D) Relative mRNA expression of 
IL-6 and IL-6 receptor to GADPH in lung lysates. The results were expressed as means ± SEM 
of 5-6 lung lysates per group. Statistical differences (*P< 0.05, **P< 0.01, ***P< 0.001) were 
determined using t test. 
 Figure 6: Dysregulated expression of genes regarding transforming growth factor-β (TGF-
β)/bone morphogenic protein (BMP) pathway and hypoxia inducible factor-1α (HIF-1α) 
signaling machinery in mice exposed to hypoxia combined with/without SU5416. (A, B) 
Representative immunoblot protein expression of HIF-1α and pSmad3 and (C, D) quantification 
of HIF-1α and pSmad3, respectively. Immunoblots were representative of lungs from 4 
individuals for each group. (E, F) Relative mRNA expression of TGF-β and BMPRII to GAPDH. 
The results were expressed as means ± SEM of 5-6 lung lysates per group. Statistical differences 
(*P< 0.05, **P< 0.01, ***P< 0.001) were determined using t test. 
Figure 7: Lung profiling from hypoxia combined SU5416-treated mice showed 
dysregulation of genes regarding endothelin signaling machinery, whereas no change in 
hypoxic mice. (A, B, D) Relative mRNA expression of ET-1, ETAR and ETBR to GADPH in 
lung lysates of normoxic, hypoxic, and hypoxia combined SU5416-treated mice normalized to 
normoxia group, (n=5-6). (C) Representative protein expression of ETAR from lungs of 
normoxic, hypoxic and hypoxia combined SU5416-treated mice. Densitometry was performed 
and normalized for GAPDH, (n=4). (E) Double immunofluorescent staining with antibody anti-
SMA and ETAR showed the expression of ETAR in medial layer (SMA staining) in pulmonary 
arterioles of hypoxia combined SU5416-treated mice, but not in that of hypoxic and normoxic 
ones. Scale bars: 50 μm. Statistical differences (*P < 0.05, **P< 0.01) were determined using t 
test.  
 
Figure 8: Effects of hypoxia (1% O2), hypoxia combined with SU5416 (15nM) on IL-6 
expression in activated macrophages transformed from human monocytic cell line (THP-1) 
under phorbol myristate acetate (PMA) treatment. (A) Relative mRNA expression of IL-6 
normalized to 18S, (n=4). (B) Representative immunoblot and quantification of IL-6 (n=4). 
GAPDH was used as a loading control, (n=4). Statistical differences (*P< 0.05, **P< 0.01) were 
determined using t test.  
 
Figure 9: Effect of IL-6 treatment (50ng/ml) on ET-1, ETBR expression and proliferation of 
MS1 (mouse pancreatic endothelial cell line) and primary mouse pulmonary endothelial cells 
(pmPECs). (A, B, D, E) Relative mRNA expression of ET-1, ETBR to GAPDH in MS1 (A, B) 
and pmPECs (D, E) normalized to control. (C) IL-6 stimulated MS1 proliferation measured by 
WST-1 assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 Table 1: List of primers 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward primers (5’-3’) Reverse primers (5’-3’) 
mMCP1 
mGAPDH 
mBMPRII 
mIL-6 
mIL-6R 
mMMP-9  
mETBR 
mETAR 
mET-1 
mBcl-2 
mVEGF-A 
mVEGF-R2 
mTGF-β 
h18S 
hIL-6 
GCATCCACGTGTTGGCTCA 
TGTGTCCGTCGTGGATCTGA 
GAGCCCTCCCTTGACCTG 
GCTACCAAACTGGATATAATCAGGA 
ATCCTCTGGAACCCCACAC 
GCCTGGCACATAGTAGGCCC 
CATGCGCAATGGTCCCAATA 
GCTGGTTCCCTCTTCACTTAAGC 
GCCACAGACCAGGCAGTTAGA 
GTGTTCCATGCACCAAGTCCA 
CAGTTCGAGGAAAGGGAAAGG 
CCTACCTCACCTGTTTCCTGTATG 
TTCCGCTGCTACTGCAAGTCA 
GTAACCCGTTGAACCCCATTTTCGGT
CCAGTTGCCTTCTC 
CTCCAGCCTACTCATTGGGATCA 
TTGCTGTTGAAGTCGCAGGAG 
GTATCGACCCCGTCCAATC 
CCAGGTAGCTATGGTACTCCAGAA 
GAACTTTCGTACTGATCCTCGTG 
CTTCCTAGCCAGCCGGCATC 
GCTCCAAATGGCCAGTCCTC 
TCATGGTTGCCAGGTTAATGC 
CACCAGCTGCTGATAGATACACTTC 
AGGTACAGGCATTGCCGCATA 
CACGTCTGCGGATCTTGGAC 
ACCATCCCACTGTCTGTCTGG 
GGGTAGCGATCGAGTGTCCA 
CCATCCAATCGGTAGTAGCG 
GAGGTGAGTGGCTGTCTGTG 
 Table 2: Baseline body weight, final body weight, and heart rate after injection of SU5416 or 
vehicle and exposure for 3 weeks to 10% O2 (hypoxia) or room air (normoxia) 
 
Normoxia Hypoxia Hypoxia+SU 
 n= 6 n=6 n=5 
Baseline body weight (g) 9.58 ± 0.37 9.72 ± 0.27 9.92 ± 0.21 
Final body weight (g) 19.90 ± 0.72 18.80 ± 0.57 17.23 ± 0.49 A,B 
Heart rate (bmp) 370 ± 15 383 ± 20 392 ± 23 
 
 
All values are the mean ± SEM. A: P< 0.01 versus normoxia and B: P< 0.05 versus hypoxia. 
Heart rate: measured while recording right ventricular systolic pressure (RVSP)  
 
